English

ANTARES PHARMA, INC.

EDGAR

ATRS Quarterly report (10-Q) · filed 2022-05-10

223 filing records in this dataset, filed from 1996-11-13 to 2022-05-10. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

41.6 million USD

2022 Q1 · USD

Exact inputs and evidence

Revenue: 41557000 USD Source

Operating margin

-6.79%

2022 Q1 · %

Exact inputs and evidence

Operating Income: -2820000 USD Source
Revenue: 41557000 USD Source

Operating cash flow

-4.88 million USD

2022 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -4881000 USD Source

Free cash flow

-4.96 million USD

2022 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -4881000 USD Source
Capital Expenditure: 81000 USD Source

Cash and cash equivalents: 61.7 million USD 2022-03-31 Source
Exact value

61715000 USD
Long-term debt including current maturities: 19.6 million USD 2022-03-31 Source
Exact value

19625000 USD
Shares outstanding: 171 million shares 2022-03-31 Source
Exact value

170580000 shares

Reported share-count change

1.06% · 1.78 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

168798000 shares · 2021-03-31· Source
170580000 shares · 2022-03-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-05-10.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2021-12-31
Operating income: 11 of 11 periods available· newest 2021-12-31
Net income: 11 of 11 periods available· newest 2021-12-31
Operating cash flow: 11 of 11 periods available· newest 2021-12-31
Capital expenditure: 11 of 11 periods available· newest 2021-12-31
Total assets: 11 of 11 periods available· newest 2021-12-31
Total liabilities: 11 of 11 periods available· newest 2021-12-31
Current assets: 11 of 11 periods available· newest 2021-12-31
Current liabilities: 11 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2021-12-31
Long-term debt including current maturities: 5 of 11 periods available· newest 2021-12-31
Shares outstanding: 11 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+23%

Prior period

USD 149.6 million

2020-01-01 – 2020-12-31
Current period

USD 183.98 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

183982000 − 149599000 = 34383000 USD

149599000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
183982000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ANTARES PHARMA, INC. · 2021-12-31 ANTARES PHARMA, INC. (edgar:1016169) Year-over-year change in Revenue: 34383000 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 183982000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#2198245 Filing: 000101616922000028 Input fundies:Revenue: 149599000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#2199642 Filing: 000101616922000028
The citation records this snapshot. The page link may show a newer release later.
Net income
-17.6%

Prior period

USD 56.2 million

2020-01-01 – 2020-12-31
Current period

USD 46.29 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

46289000 − 56201000 = -9912000 USD

56201000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
46289000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ANTARES PHARMA, INC. · 2021-12-31 ANTARES PHARMA, INC. (edgar:1016169) Year-over-year change in Net income: -9912000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 46289000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#2223632 Filing: 000101616922000028 Input fundies:NetIncome: 56201000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#2224876 Filing: 000101616922000028
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+71.8%

Prior period

USD 21.32 million

2020-01-01 – 2020-12-31
Current period

USD 36.62 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

36619000 − 21320000 = 15299000 USD

21320000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
36619000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ANTARES PHARMA, INC. · 2021-12-31 ANTARES PHARMA, INC. (edgar:1016169) Year-over-year change in Operating cash flow: 15299000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 36619000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1308885 Filing: 000101616922000028 Input fundies:OperatingCashFlow: 21320000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1309930 Filing: 000101616922000028
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-31.2%

Prior period

USD 9.62 million

2020-01-01 – 2020-12-31
Current period

USD 6.62 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

6617000 − 9615000 = -2998000 USD

9615000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
6617000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ANTARES PHARMA, INC. · 2021-12-31 ANTARES PHARMA, INC. (edgar:1016169) Year-over-year change in Capital expenditure: -2998000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 6617000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1312913 Filing: 000101616922000028 Input fundies:CapitalExpenditure: 9615000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1313895 Filing: 000101616922000028
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 183.98 million 100% of revenue
Operating costs Derived USD 118.05 million 64% of revenue
Operating income USD 65.93 million 36% of revenue
Tax, interest and other Derived USD 19.64 million 11% of revenue
Net income USD 46.29 million 25% of revenue

Cash

Operating cash flow USD 36.62 million 20% of revenue
Capital expenditure USD 6.62 million 3.6% of revenue
Free cash flow Derived USD 30 million 16% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2012 Operating loss: operating costs were 151% of revenue.
2013 Operating loss: operating costs were 201% of revenue.
2014 Operating loss: operating costs were 232% of revenue.
2015 Operating loss: operating costs were 145% of revenue.
2016 Operating loss: operating costs were 146% of revenue.
2017 Operating loss: operating costs were 129% of revenue.
2018 Operating loss: operating costs were 106% of revenue.
2019 Net loss: net income was −1.6% of revenue.
2020 Net income was higher than operating income, so the split is not drawn.
2021 25%11%64%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2012 2012-01-01 – 2012-12-31	22575578	34027077 Derived	-11451499	-24049 Derived	-11427450	-13729620 Derived	Source 2012-01-01 – 2012-12-31: 22575578 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -11451499 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -11427450 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -10472988 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 3256632 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	20618500	41468817 Derived	-20850317	-343541 Derived	-20506776	-17711404 Derived	Source 2013-01-01 – 2013-12-31: 20618500 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -20850317 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -20506776 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -14968151 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 2743253 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	26501665	61614960 Derived	-35113295	38420 Derived	-35151715	-30996614 Derived	Source 2014-01-01 – 2014-12-31: 26501665 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -35113295 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -35151715 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -26333301 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 4663313 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	45658000	66120000 Derived	-20462000	197000 Derived	-20659000	-33842000 Derived	Source 2015-01-01 – 2015-12-31: 45658000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -20462000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -20659000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -28199000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 5643000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	52222000	76339000 Derived	-24117000	222000 Derived	-24339000	-20075000 Derived	Source 2016-01-01 – 2016-12-31: 52222000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -24117000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -24339000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -15195000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 4880000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	54515000	70106000 Derived	-15591000	1152000 Derived	-16743000	-24261000 Derived	Source 2017-01-01 – 2017-12-31: 54515000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -15591000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -16743000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -23094000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 1167000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	63554000	67655000 Derived	-4101000	2414000 Derived	-6515000	-18176000 Derived	Source 2018-01-01 – 2018-12-31: 63554000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -4101000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -6515000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -17322000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 854000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	123864000	122872000 Derived	992000	3019000 Derived	-2027000	-12965000 Derived	Source 2019-01-01 – 2019-12-31: 123864000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: 992000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -2027000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -10615000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 2350000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	149599000	135980000 Derived	13619000	-42582000 Derived	56201000	11705000 Derived	Source 2020-01-01 – 2020-12-31: 149599000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 13619000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 56201000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 21320000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 9615000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	183982000	118049000 Derived	65933000	19644000 Derived	46289000	30002000 Derived	Source 2021-01-01 – 2021-12-31: 183982000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 65933000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 46289000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 36619000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 6617000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 184M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Revenue	22575578	Revenue: 22575578 Open source
20132013-12-31	Revenue	20618500	Revenue: 20618500 Open source
20142014-12-31	Revenue	26501665	Revenue: 26501665 Open source
20152015-12-31	Revenue	45658000	Revenue: 45658000 Open source
20162016-12-31	Revenue	52222000	Revenue: 52222000 Open source
20172017-12-31	Revenue	54515000	Revenue: 54515000 Open source
20182018-12-31	Revenue	63554000	Revenue: 63554000 Open source
20192019-12-31	Revenue	123864000	Revenue: 123864000 Open source
20202020-12-31	Revenue	149599000	Revenue: 149599000 Open source
20212021-12-31	Revenue	183982000	Revenue: 183982000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

23% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Year over year	37.2%	Revenue: 22575578 Open source Revenue: 16458492 Open source
20132013-12-31	Year over year	-8.7%	Revenue: 20618500 Open source Revenue: 22575578 Open source
20142014-12-31	Year over year	28.5%	Revenue: 26501665 Open source Revenue: 20618500 Open source
20152015-12-31	Year over year	72.3%	Revenue: 45658000 Open source Revenue: 26501665 Open source
20162016-12-31	Year over year	14.4%	Revenue: 52222000 Open source Revenue: 45658000 Open source
20172017-12-31	Year over year	4.4%	Revenue: 54515000 Open source Revenue: 52222000 Open source
20182018-12-31	Year over year	16.6%	Revenue: 63554000 Open source Revenue: 54515000 Open source
20192019-12-31	Year over year	94.9%	Revenue: 123864000 Open source Revenue: 63554000 Open source
20202020-12-31	Year over year	20.8%	Revenue: 149599000 Open source Revenue: 123864000 Open source
20212021-12-31	Year over year	23%	Revenue: 183982000 Open source Revenue: 149599000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 35.8% 2021

Net margin 25.2% 2021

Free cash flow margin 16.3% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Operating margin	-50.7%	Operating Income: -11451499 Open source Revenue: 22575578 Open source
20132013-12-31	Operating margin	-101.1%	Operating Income: -20850317 Open source Revenue: 20618500 Open source
20142014-12-31	Operating margin	-132.5%	Operating Income: -35113295 Open source Revenue: 26501665 Open source
20152015-12-31	Operating margin	-44.8%	Operating Income: -20462000 Open source Revenue: 45658000 Open source
20162016-12-31	Operating margin	-46.2%	Operating Income: -24117000 Open source Revenue: 52222000 Open source
20172017-12-31	Operating margin	-28.6%	Operating Income: -15591000 Open source Revenue: 54515000 Open source
20182018-12-31	Operating margin	-6.5%	Operating Income: -4101000 Open source Revenue: 63554000 Open source
20192019-12-31	Operating margin	0.8%	Operating Income: 992000 Open source Revenue: 123864000 Open source
20202020-12-31	Operating margin	9.1%	Operating Income: 13619000 Open source Revenue: 149599000 Open source
20212021-12-31	Operating margin	35.8%	Operating Income: 65933000 Open source Revenue: 183982000 Open source
20122012-12-31	Net margin	-50.6%	Net Income: -11427450 Open source Revenue: 22575578 Open source
20132013-12-31	Net margin	-99.5%	Net Income: -20506776 Open source Revenue: 20618500 Open source
20142014-12-31	Net margin	-132.6%	Net Income: -35151715 Open source Revenue: 26501665 Open source
20152015-12-31	Net margin	-45.2%	Net Income: -20659000 Open source Revenue: 45658000 Open source
20162016-12-31	Net margin	-46.6%	Net Income: -24339000 Open source Revenue: 52222000 Open source
20172017-12-31	Net margin	-30.7%	Net Income: -16743000 Open source Revenue: 54515000 Open source
20182018-12-31	Net margin	-10.3%	Net Income: -6515000 Open source Revenue: 63554000 Open source
20192019-12-31	Net margin	-1.6%	Net Income: -2027000 Open source Revenue: 123864000 Open source
20202020-12-31	Net margin	37.6%	Net Income: 56201000 Open source Revenue: 149599000 Open source
20212021-12-31	Net margin	25.2%	Net Income: 46289000 Open source Revenue: 183982000 Open source
20122012-12-31	Free cash flow margin	-60.8%	Revenue: 22575578 Open source Operating Cash Flow: -10472988 Open source Capital Expenditure: 3256632 Open source
20132013-12-31	Free cash flow margin	-85.9%	Revenue: 20618500 Open source Operating Cash Flow: -14968151 Open source Capital Expenditure: 2743253 Open source
20142014-12-31	Free cash flow margin	-117%	Revenue: 26501665 Open source Operating Cash Flow: -26333301 Open source Capital Expenditure: 4663313 Open source
20152015-12-31	Free cash flow margin	-74.1%	Revenue: 45658000 Open source Operating Cash Flow: -28199000 Open source Capital Expenditure: 5643000 Open source
20162016-12-31	Free cash flow margin	-38.4%	Revenue: 52222000 Open source Operating Cash Flow: -15195000 Open source Capital Expenditure: 4880000 Open source
20172017-12-31	Free cash flow margin	-44.5%	Revenue: 54515000 Open source Operating Cash Flow: -23094000 Open source Capital Expenditure: 1167000 Open source
20182018-12-31	Free cash flow margin	-28.6%	Revenue: 63554000 Open source Operating Cash Flow: -17322000 Open source Capital Expenditure: 854000 Open source
20192019-12-31	Free cash flow margin	-10.5%	Revenue: 123864000 Open source Operating Cash Flow: -10615000 Open source Capital Expenditure: 2350000 Open source
20202020-12-31	Free cash flow margin	7.8%	Revenue: 149599000 Open source Operating Cash Flow: 21320000 Open source Capital Expenditure: 9615000 Open source
20212021-12-31	Free cash flow margin	16.3%	Revenue: 183982000 Open source Operating Cash Flow: 36619000 Open source Capital Expenditure: 6617000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 36.6M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Operating cash flow	-10472988	Operating Cash Flow: -10472988 Open source
20132013-12-31	Operating cash flow	-14968151	Operating Cash Flow: -14968151 Open source
20142014-12-31	Operating cash flow	-26333301	Operating Cash Flow: -26333301 Open source
20152015-12-31	Operating cash flow	-28199000	Operating Cash Flow: -28199000 Open source
20162016-12-31	Operating cash flow	-15195000	Operating Cash Flow: -15195000 Open source
20172017-12-31	Operating cash flow	-23094000	Operating Cash Flow: -23094000 Open source
20182018-12-31	Operating cash flow	-17322000	Operating Cash Flow: -17322000 Open source
20192019-12-31	Operating cash flow	-10615000	Operating Cash Flow: -10615000 Open source
20202020-12-31	Operating cash flow	21320000	Operating Cash Flow: 21320000 Open source
20212021-12-31	Operating cash flow	36619000	Operating Cash Flow: 36619000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 30M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Free cash flow	-13729620	Operating Cash Flow: -10472988 Open source Capital Expenditure: 3256632 Open source
20132013-12-31	Free cash flow	-17711404	Operating Cash Flow: -14968151 Open source Capital Expenditure: 2743253 Open source
20142014-12-31	Free cash flow	-30996614	Operating Cash Flow: -26333301 Open source Capital Expenditure: 4663313 Open source
20152015-12-31	Free cash flow	-33842000	Operating Cash Flow: -28199000 Open source Capital Expenditure: 5643000 Open source
20162016-12-31	Free cash flow	-20075000	Operating Cash Flow: -15195000 Open source Capital Expenditure: 4880000 Open source
20172017-12-31	Free cash flow	-24261000	Operating Cash Flow: -23094000 Open source Capital Expenditure: 1167000 Open source
20182018-12-31	Free cash flow	-18176000	Operating Cash Flow: -17322000 Open source Capital Expenditure: 854000 Open source
20192019-12-31	Free cash flow	-12965000	Operating Cash Flow: -10615000 Open source Capital Expenditure: 2350000 Open source
20202020-12-31	Free cash flow	11705000	Operating Cash Flow: 21320000 Open source Capital Expenditure: 9615000 Open source
20212021-12-31	Free cash flow	30002000	Operating Cash Flow: 36619000 Open source Capital Expenditure: 6617000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

31.7% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Liabilities / assets	9.4%	Total Liabilities: 8976018 Open source Total Assets: 95526610 Open source
20132013-12-31	Liabilities / assets	20.5%	Total Liabilities: 18218203 Open source Total Assets: 88931931 Open source
20142014-12-31	Liabilities / assets	40.1%	Total Liabilities: 27576606 Open source Total Assets: 68772762 Open source
20152015-12-31	Liabilities / assets	20.7%	Total Liabilities: 17519560 Open source Total Assets: 84562171 Open source
20162016-12-31	Liabilities / assets	31.8%	Total Liabilities: 21107000 Open source Total Assets: 66325000 Open source
20172017-12-31	Liabilities / assets	54.9%	Total Liabilities: 40791000 Open source Total Assets: 74338000 Open source
20182018-12-31	Liabilities / assets	55.8%	Total Liabilities: 49276000 Open source Total Assets: 88277000 Open source
20192019-12-31	Liabilities / assets	58.9%	Total Liabilities: 78251000 Open source Total Assets: 132751000 Open source
20202020-12-31	Liabilities / assets	44%	Total Liabilities: 93416000 Open source Total Assets: 212531000 Open source
20212021-12-31	Liabilities / assets	31.7%	Total Liabilities: 81747000 Open source Total Assets: 257505000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.96× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Current assets / current liabilities	9.78×	Current Assets: 77659232 Open source Current Liabilities: 7938223 Open source
20132013-12-31	Current assets / current liabilities	4.44×	Current Assets: 72659535 Open source Current Liabilities: 16363007 Open source
20142014-12-31	Current assets / current liabilities	2.21×	Current Assets: 53637687 Open source Current Liabilities: 24227580 Open source
20152015-12-31	Current assets / current liabilities	3.93×	Current Assets: 66061247 Open source Current Liabilities: 16819560 Open source
20162016-12-31	Current assets / current liabilities	2.27×	Current Assets: 45264000 Open source Current Liabilities: 19907000 Open source
20172017-12-31	Current assets / current liabilities	3.53×	Current Assets: 55536000 Open source Current Liabilities: 15733000 Open source
20182018-12-31	Current assets / current liabilities	2.62×	Current Assets: 71308000 Open source Current Liabilities: 27193000 Open source
20192019-12-31	Current assets / current liabilities	3.35×	Current Assets: 108446000 Open source Current Liabilities: 32415000 Open source
20202020-12-31	Current assets / current liabilities	2×	Current Assets: 126591000 Open source Current Liabilities: 63205000 Open source
20212021-12-31	Current assets / current liabilities	2.96×	Current Assets: 174272000 Open source Current Liabilities: 58930000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	−USD 11.43 million Exact value Exact value: -11427450 USD 2012-01-01 – 2012-12-31: -11427450 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANTARES PHARMA, INC. · 2012-12-31 ANTARES PHARMA, INC. (edgar:1016169) Net Income: -11427450 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11427450 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000119312515088373/atrs-20141231.xml#702540 Filing: 000119312515088373 The citation records this snapshot. The page link may show a newer release later.	−USD 10.47 million Exact value Exact value: -10472988 USD 2012-01-01 – 2012-12-31: -10472988 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANTARES PHARMA, INC. · 2012-12-31 ANTARES PHARMA, INC. (edgar:1016169) Operating Cash Flow: -10472988 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10472988 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000119312515088373/atrs-20141231.xml#690616 Filing: 000119312515088373 The citation records this snapshot. The page link may show a newer release later.	USD 3.26 million Exact value Exact value: 3256632 USD 2012-01-01 – 2012-12-31: 3256632 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANTARES PHARMA, INC. · 2012-12-31 ANTARES PHARMA, INC. (edgar:1016169) Capital Expenditure: 3256632 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3256632 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000119312515088373/atrs-20141231.xml#702275 Filing: 000119312515088373 The citation records this snapshot. The page link may show a newer release later.	−USD 13.73 million Calculation and evidence -10472988 − 3256632 USD Exact free cash flow: -13729620 USD 2012-01-01 – 2012-12-31: -10472988 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 3256632 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANTARES PHARMA, INC. · 2012-12-31 ANTARES PHARMA, INC. (edgar:1016169) Free cash flow: -13729620 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10472988 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000119312515088373/atrs-20141231.xml#690616 Filing: 000119312515088373 Input fundies:CapitalExpenditure: 3256632 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000119312515088373/atrs-20141231.xml#702275 Filing: 000119312515088373 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 20.51 million Exact value Exact value: -20506776 USD 2013-01-01 – 2013-12-31: -20506776 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANTARES PHARMA, INC. · 2013-12-31 ANTARES PHARMA, INC. (edgar:1016169) Net Income: -20506776 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20506776 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459016014226/atrs-20151231.xml#99248 Filing: 000156459016014226 The citation records this snapshot. The page link may show a newer release later.	−USD 14.97 million Exact value Exact value: -14968151 USD 2013-01-01 – 2013-12-31: -14968151 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANTARES PHARMA, INC. · 2013-12-31 ANTARES PHARMA, INC. (edgar:1016169) Operating Cash Flow: -14968151 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14968151 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459016014226/atrs-20151231.xml#127202 Filing: 000156459016014226 The citation records this snapshot. The page link may show a newer release later.	USD 2.74 million Exact value Exact value: 2743253 USD 2013-01-01 – 2013-12-31: 2743253 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANTARES PHARMA, INC. · 2013-12-31 ANTARES PHARMA, INC. (edgar:1016169) Capital Expenditure: 2743253 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2743253 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459016014226/atrs-20151231.xml#127871 Filing: 000156459016014226 The citation records this snapshot. The page link may show a newer release later.	−USD 17.71 million Calculation and evidence -14968151 − 2743253 USD Exact free cash flow: -17711404 USD 2013-01-01 – 2013-12-31: -14968151 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 2743253 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANTARES PHARMA, INC. · 2013-12-31 ANTARES PHARMA, INC. (edgar:1016169) Free cash flow: -17711404 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14968151 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459016014226/atrs-20151231.xml#127202 Filing: 000156459016014226 Input fundies:CapitalExpenditure: 2743253 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459016014226/atrs-20151231.xml#127871 Filing: 000156459016014226 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 35.15 million Exact value Exact value: -35151715 USD 2014-01-01 – 2014-12-31: -35151715 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANTARES PHARMA, INC. · 2014-12-31 ANTARES PHARMA, INC. (edgar:1016169) Net Income: -35151715 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35151715 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459017004282/atrs-20161231.xml#89838 Filing: 000156459017004282 The citation records this snapshot. The page link may show a newer release later.	−USD 26.33 million Exact value Exact value: -26333301 USD 2014-01-01 – 2014-12-31: -26333301 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANTARES PHARMA, INC. · 2014-12-31 ANTARES PHARMA, INC. (edgar:1016169) Operating Cash Flow: -26333301 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26333301 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459017004282/atrs-20161231.xml#117938 Filing: 000156459017004282 The citation records this snapshot. The page link may show a newer release later.	USD 4.66 million Exact value Exact value: 4663313 USD 2014-01-01 – 2014-12-31: 4663313 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANTARES PHARMA, INC. · 2014-12-31 ANTARES PHARMA, INC. (edgar:1016169) Capital Expenditure: 4663313 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4663313 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459017004282/atrs-20161231.xml#118607 Filing: 000156459017004282 The citation records this snapshot. The page link may show a newer release later.	−USD 31 million Calculation and evidence -26333301 − 4663313 USD Exact free cash flow: -30996614 USD 2014-01-01 – 2014-12-31: -26333301 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 4663313 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANTARES PHARMA, INC. · 2014-12-31 ANTARES PHARMA, INC. (edgar:1016169) Free cash flow: -30996614 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26333301 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459017004282/atrs-20161231.xml#117938 Filing: 000156459017004282 Input fundies:CapitalExpenditure: 4663313 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459017004282/atrs-20161231.xml#118607 Filing: 000156459017004282 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 20.66 million Exact value Exact value: -20659000 USD 2015-01-01 – 2015-12-31: -20659000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANTARES PHARMA, INC. · 2015-12-31 ANTARES PHARMA, INC. (edgar:1016169) Net Income: -20659000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20659000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459018005459/atrs-20171231.xml#91698 Filing: 000156459018005459 The citation records this snapshot. The page link may show a newer release later.	−USD 28.2 million Exact value Exact value: -28199000 USD 2015-01-01 – 2015-12-31: -28199000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANTARES PHARMA, INC. · 2015-12-31 ANTARES PHARMA, INC. (edgar:1016169) Operating Cash Flow: -28199000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28199000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459018005459/atrs-20171231.xml#120790 Filing: 000156459018005459 The citation records this snapshot. The page link may show a newer release later.	USD 5.64 million Exact value Exact value: 5643000 USD 2015-01-01 – 2015-12-31: 5643000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANTARES PHARMA, INC. · 2015-12-31 ANTARES PHARMA, INC. (edgar:1016169) Capital Expenditure: 5643000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5643000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459018005459/atrs-20171231.xml#121462 Filing: 000156459018005459 The citation records this snapshot. The page link may show a newer release later.	−USD 33.84 million Calculation and evidence -28199000 − 5643000 USD Exact free cash flow: -33842000 USD 2015-01-01 – 2015-12-31: -28199000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 5643000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANTARES PHARMA, INC. · 2015-12-31 ANTARES PHARMA, INC. (edgar:1016169) Free cash flow: -33842000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28199000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459018005459/atrs-20171231.xml#120790 Filing: 000156459018005459 Input fundies:CapitalExpenditure: 5643000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459018005459/atrs-20171231.xml#121462 Filing: 000156459018005459 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 24.34 million Exact value Exact value: -24339000 USD 2016-01-01 – 2016-12-31: -24339000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANTARES PHARMA, INC. · 2016-12-31 ANTARES PHARMA, INC. (edgar:1016169) Net Income: -24339000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24339000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459019007398/atrs-20181231.xml#128453 Filing: 000156459019007398 The citation records this snapshot. The page link may show a newer release later.	−USD 15.2 million Exact value Exact value: -15195000 USD 2016-01-01 – 2016-12-31: -15195000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANTARES PHARMA, INC. · 2016-12-31 ANTARES PHARMA, INC. (edgar:1016169) Operating Cash Flow: -15195000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15195000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459019007398/atrs-20181231.xml#157426 Filing: 000156459019007398 The citation records this snapshot. The page link may show a newer release later.	USD 4.88 million Exact value Exact value: 4880000 USD 2016-01-01 – 2016-12-31: 4880000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANTARES PHARMA, INC. · 2016-12-31 ANTARES PHARMA, INC. (edgar:1016169) Capital Expenditure: 4880000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4880000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459019007398/atrs-20181231.xml#158057 Filing: 000156459019007398 The citation records this snapshot. The page link may show a newer release later.	−USD 20.08 million Calculation and evidence -15195000 − 4880000 USD Exact free cash flow: -20075000 USD 2016-01-01 – 2016-12-31: -15195000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 4880000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANTARES PHARMA, INC. · 2016-12-31 ANTARES PHARMA, INC. (edgar:1016169) Free cash flow: -20075000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15195000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459019007398/atrs-20181231.xml#157426 Filing: 000156459019007398 Input fundies:CapitalExpenditure: 4880000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459019007398/atrs-20181231.xml#158057 Filing: 000156459019007398 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 16.74 million Exact value Exact value: -16743000 USD 2017-01-01 – 2017-12-31: -16743000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANTARES PHARMA, INC. · 2017-12-31 ANTARES PHARMA, INC. (edgar:1016169) Net Income: -16743000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16743000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459020008465/atrs-10k_20191231.htm#1930141 Filing: 000156459020008465 The citation records this snapshot. The page link may show a newer release later.	−USD 23.09 million Exact value Exact value: -23094000 USD 2017-01-01 – 2017-12-31: -23094000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANTARES PHARMA, INC. · 2017-12-31 ANTARES PHARMA, INC. (edgar:1016169) Operating Cash Flow: -23094000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23094000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459020008465/atrs-10k_20191231.htm#2233772 Filing: 000156459020008465 The citation records this snapshot. The page link may show a newer release later.	USD 1.17 million Exact value Exact value: 1167000 USD 2017-01-01 – 2017-12-31: 1167000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANTARES PHARMA, INC. · 2017-12-31 ANTARES PHARMA, INC. (edgar:1016169) Capital Expenditure: 1167000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1167000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459020008465/atrs-10k_20191231.htm#2250722 Filing: 000156459020008465 The citation records this snapshot. The page link may show a newer release later.	−USD 24.26 million Calculation and evidence -23094000 − 1167000 USD Exact free cash flow: -24261000 USD 2017-01-01 – 2017-12-31: -23094000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1167000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANTARES PHARMA, INC. · 2017-12-31 ANTARES PHARMA, INC. (edgar:1016169) Free cash flow: -24261000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23094000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459020008465/atrs-10k_20191231.htm#2233772 Filing: 000156459020008465 Input fundies:CapitalExpenditure: 1167000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459020008465/atrs-10k_20191231.htm#2250722 Filing: 000156459020008465 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 6.52 million Exact value Exact value: -6515000 USD 2018-01-01 – 2018-12-31: -6515000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANTARES PHARMA, INC. · 2018-12-31 ANTARES PHARMA, INC. (edgar:1016169) Net Income: -6515000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6515000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459021010298/atrs-10k_20201231.htm#3467657 Filing: 000156459021010298 The citation records this snapshot. The page link may show a newer release later.	−USD 17.32 million Exact value Exact value: -17322000 USD 2018-01-01 – 2018-12-31: -17322000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANTARES PHARMA, INC. · 2018-12-31 ANTARES PHARMA, INC. (edgar:1016169) Operating Cash Flow: -17322000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17322000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459021010298/atrs-10k_20201231.htm#2076679 Filing: 000156459021010298 The citation records this snapshot. The page link may show a newer release later.	USD 854,000 Exact value Exact value: 854000 USD 2018-01-01 – 2018-12-31: 854000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANTARES PHARMA, INC. · 2018-12-31 ANTARES PHARMA, INC. (edgar:1016169) Capital Expenditure: 854000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 854000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459021010298/atrs-10k_20201231.htm#2098853 Filing: 000156459021010298 The citation records this snapshot. The page link may show a newer release later.	−USD 18.18 million Calculation and evidence -17322000 − 854000 USD Exact free cash flow: -18176000 USD 2018-01-01 – 2018-12-31: -17322000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 854000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANTARES PHARMA, INC. · 2018-12-31 ANTARES PHARMA, INC. (edgar:1016169) Free cash flow: -18176000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17322000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459021010298/atrs-10k_20201231.htm#2076679 Filing: 000156459021010298 Input fundies:CapitalExpenditure: 854000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000156459021010298/atrs-10k_20201231.htm#2098853 Filing: 000156459021010298 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 2.03 million Exact value Exact value: -2027000 USD 2019-01-01 – 2019-12-31: -2027000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANTARES PHARMA, INC. · 2019-12-31 ANTARES PHARMA, INC. (edgar:1016169) Net Income: -2027000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2027000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#2226121 Filing: 000101616922000028 The citation records this snapshot. The page link may show a newer release later.	−USD 10.62 million Exact value Exact value: -10615000 USD 2019-01-01 – 2019-12-31: -10615000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANTARES PHARMA, INC. · 2019-12-31 ANTARES PHARMA, INC. (edgar:1016169) Operating Cash Flow: -10615000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10615000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1310976 Filing: 000101616922000028 The citation records this snapshot. The page link may show a newer release later.	USD 2.35 million Exact value Exact value: 2350000 USD 2019-01-01 – 2019-12-31: 2350000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANTARES PHARMA, INC. · 2019-12-31 ANTARES PHARMA, INC. (edgar:1016169) Capital Expenditure: 2350000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2350000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1314877 Filing: 000101616922000028 The citation records this snapshot. The page link may show a newer release later.	−USD 12.97 million Calculation and evidence -10615000 − 2350000 USD Exact free cash flow: -12965000 USD 2019-01-01 – 2019-12-31: -10615000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 2350000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANTARES PHARMA, INC. · 2019-12-31 ANTARES PHARMA, INC. (edgar:1016169) Free cash flow: -12965000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10615000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1310976 Filing: 000101616922000028 Input fundies:CapitalExpenditure: 2350000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1314877 Filing: 000101616922000028 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 56.2 million Exact value Exact value: 56201000 USD 2020-01-01 – 2020-12-31: 56201000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANTARES PHARMA, INC. · 2020-12-31 ANTARES PHARMA, INC. (edgar:1016169) Net Income: 56201000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 56201000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#2224876 Filing: 000101616922000028 The citation records this snapshot. The page link may show a newer release later.	USD 21.32 million Exact value Exact value: 21320000 USD 2020-01-01 – 2020-12-31: 21320000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANTARES PHARMA, INC. · 2020-12-31 ANTARES PHARMA, INC. (edgar:1016169) Operating Cash Flow: 21320000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 21320000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1309930 Filing: 000101616922000028 The citation records this snapshot. The page link may show a newer release later.	USD 9.62 million Exact value Exact value: 9615000 USD 2020-01-01 – 2020-12-31: 9615000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANTARES PHARMA, INC. · 2020-12-31 ANTARES PHARMA, INC. (edgar:1016169) Capital Expenditure: 9615000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9615000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1313895 Filing: 000101616922000028 The citation records this snapshot. The page link may show a newer release later.	USD 11.71 million Calculation and evidence 21320000 − 9615000 USD Exact free cash flow: 11705000 USD 2020-01-01 – 2020-12-31: 21320000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 9615000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANTARES PHARMA, INC. · 2020-12-31 ANTARES PHARMA, INC. (edgar:1016169) Free cash flow: 11705000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 21320000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1309930 Filing: 000101616922000028 Input fundies:CapitalExpenditure: 9615000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1313895 Filing: 000101616922000028 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 46.29 million Exact value Exact value: 46289000 USD 2021-01-01 – 2021-12-31: 46289000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANTARES PHARMA, INC. · 2021-12-31 ANTARES PHARMA, INC. (edgar:1016169) Net Income: 46289000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 46289000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#2223632 Filing: 000101616922000028 The citation records this snapshot. The page link may show a newer release later.	USD 36.62 million Exact value Exact value: 36619000 USD 2021-01-01 – 2021-12-31: 36619000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANTARES PHARMA, INC. · 2021-12-31 ANTARES PHARMA, INC. (edgar:1016169) Operating Cash Flow: 36619000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 36619000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1308885 Filing: 000101616922000028 The citation records this snapshot. The page link may show a newer release later.	USD 6.62 million Exact value Exact value: 6617000 USD 2021-01-01 – 2021-12-31: 6617000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANTARES PHARMA, INC. · 2021-12-31 ANTARES PHARMA, INC. (edgar:1016169) Capital Expenditure: 6617000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6617000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1312913 Filing: 000101616922000028 The citation records this snapshot. The page link may show a newer release later.	USD 30 million Calculation and evidence 36619000 − 6617000 USD Exact free cash flow: 30002000 USD 2021-01-01 – 2021-12-31: 36619000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 6617000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANTARES PHARMA, INC. · 2021-12-31 ANTARES PHARMA, INC. (edgar:1016169) Free cash flow: 30002000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:35:00Z Snapshot: 506e8a278c8bcba82665fb124c445c4f36bcc8c676b9d6fdb0262e637412a006 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1016169?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 36619000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1308885 Filing: 000101616922000028 Input fundies:CapitalExpenditure: 6617000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1016169/000101616922000028/atrs-20211231.htm#1312913 Filing: 000101616922000028 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

223 filings · 3,621 latest values · 3,621 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001016169, 1016169, ATRS, edgar:1016169

Also known as ANTARES PHARMA INC, ANTARES PHARMA INC, ANTARES PHARMA INC /MN/, ANTARES PHARMA, INC., Antares Pharma, Inc., MEDI JECT CORP /MN/

ANTARES PHARMA, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation